<DOC>
	<DOC>NCT01154621</DOC>
	<brief_summary>The aim of this study is to examine the safety and tolerability of a single dose of AZD9742 in elderly individuals.</brief_summary>
	<brief_title>Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects</brief_title>
	<detailed_description />
	<criteria>Male and female volunteers at age of 65 years or older with suitable veins for cannulation or repeated venipuncture, in good health (based on medical history and physical examination and clinical laboratory tests) as judged by the investigator. Female volunteers must be postmenopausal (cessation of regular menses for 12 months and a follicle stimulating hormone level of more than 40IU/L abd estradiol of less than 20ng/mL. Male volunteers should be willing to use barrier contraception, ie, condoms, from the day of dosing until 3 months after dosing with the investigational product. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate History or presence of GI, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs as judged by Investigator. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational product</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Randomized</keyword>
	<keyword>Placebo-controlled study</keyword>
	<keyword>Safety and tolerability of single intravenous dose of AZD9742 in healthy elderly volunteers</keyword>
</DOC>